Ensysce Biosciences Inc (ENSC) Stock Price, Quote & News

Company Profile

Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, develops prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, designed to release clinically effective drugs only when exposed to specific physiological conditions; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology. The company's lead product candidate is...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 263 4196

Website: www.ensysce.com

Address:

7946 Ivanhoe Avenue, Suite 201, La Jolla, United States

KelsoWins Sep. 21 at 5:07 AM

$ENSC in Friday with a starter.. I've been ALL-IN trading only one stock the last 5 months! Finally diversifying after huge win Friday in AGMH. Anybody wants to know about AGMH let me know. Otherwise.. anyone care to drop some knowledge on me about ENSC please?

0 · Reply

ThereAre4Lights Sep. 17 at 2:12 PM

$ENSC some short has been slowly unloading the past few days, check the fidelity shortable shares available and borrow rate

0 · Reply

Fowlee06 Sep. 16 at 11:55 AM

$ENSC

0 · Reply

EnsysceBiosciences Sep. 15 at 12:40 PM

$ENSC 📸 Live from PAINWeek 2025 Dr. Jeff Gudin, University of Miami Pain Center, examined the latest entrants to the analgesic toolbox—including NAV 1.8 inhibitors—and compared them to Ensysce’s Trypsin Activated Abuse Protection (TAAP™) and Multi-Pill Abuse Resistance (MPAR®) technologies, which uniquely use the body’s own chemistry to “switch on” pain relief with proper dosing and “switch off” opioid release in an overdose. #ENSC #PAINWeek #TAAP #MPAR #PainManagement #DrugSafety

0 · Reply

EnsysceBiosciences Sep. 10 at 12:59 PM

$ENSC 📸 Live from PAINWeek 2025 Dr. William Schmidt, Chief Medical Officer of Ensysce, presented to a packed room of 400+ pain experts on the promise of PF614 (TAAP™) and PF614-MPAR®. Dr. William Schmidt shared compelling data differentiating PF614 from other severe pain treatments, outlining the upcoming Phase 3 trial in acute post-surgical pain. He highlighted how TAAP™ and MPAR® could deliver superior analgesia while offering real-world overdose protection. #ENSC #PAINWeek #TAAP #MPAR #PainManagement #DrugSafety

3 · Reply

danstra1 Sep. 10 at 10:04 AM

$ENSC Old news, but it's the latest from 12 AM, this morning... https://www.otcmarkets.com/stock/ENSC/news/Ensysce-Biosciences-Initiates-Pivotal-Phase-3-Study-of-PF614---A-Next-Generation-Opioid---Designed-to-Deliver-Powerful-P?e&id=3276529

0 · Reply

HeisenbergCT Sep. 9 at 1:41 PM

$ENSC I forgot what the company name was, but it happened two years ago. A biotech popped 4000% in one day. Never forget seeing that percentage - amazing. Can that happen with ENSC - yes. Can we expect that, of course not, but the possibility is undeniable when you realize the market potential of a truly effective opioid alternative in a time when there's a crisis of addiction and overdose/misuse. Could even be likely. We'll see. By the way, that biotech stock that popped 4000% was characterized in the article I read as being "left for dead" before that happened. Which means it came out of nowhere; it was totally unexpected.

1 · Reply

EnsysceBiosciences Sep. 8 at 1:32 PM

$ENSC Last week, Ensysce Biosciences participated in PAINWeek, the largest pain conference in the world, where experts meet to share knowledge to enhance patient care. Moderated by Dr. Lynn Kirkpatrick, CEO of Ensysce, the event brought together three leading authorities in pain medicine: 🔹 Dr. Jessica McCoun, Principal Investigator at CenExel Atlanta 🔹 Dr. Jeff Gudin, University of Miami Pain Center 🔹 Dr. William Schmidt, Ensysce’s Chief Medical Officer Read more about Ensysce’s role in the event here: https://finance.yahoo.com/news/ensysce-biosciences-showcases-urgent-safer-120000471.html

1 · Reply

HeisenbergCT Sep. 8 at 12:51 PM

$ENSC there's a direct correlation between the size of my holding and the frequency and number of my posts to this board.

1 · Reply

HeisenbergCT Sep. 8 at 12:11 PM

$ENSC 8am - 8:30 (EST) is the time period to watch ENSC. When no news breaks, tune in tomorrow, and in the meantime ignore price action (for the most part). 95% of all significant company/clinical updates post by 8:30.

0 · Reply

Ensysce Biosciences Showcases Urgent Need for Safer Opioids at PAINWeek 2025 Symposium

Aug 19, 2025, 8:00 AM EDT - 4 weeks ago

Ensysce Biosciences' Geoff Birkett to Chair the Fierce New Product Planning Summit 2025

Aug 15, 2025, 8:00 AM EDT - 5 weeks ago

Diamond Equity Research Releases Update Note on Ensysce Biosciences, Inc. (NASDAQ: ENSC)

Aug 13, 2025, 4:15 PM EDT - 5 weeks ago

Ensysce Biosciences Reports Second Quarter 2025 Financial Results and Latest Program Updates

Jul 31, 2025, 8:00 AM EDT - 7 weeks ago

Ensysce Biosciences Advances Breakthrough Opioid With Built-In Overdose Protection Following Positive FDA Feedback

Jul 16, 2025, 8:00 AM EDT - 2 months ago

Ensysce Biosciences Initiates Pivotal Phase 3 Study of PF614 - A Next-Generation Opioid - Designed to Deliver Powerful Pain Relief and Reduce Abuse

Jun 24, 2025, 8:00 AM EDT - 3 months ago

Ensysce Biosciences Accelerates PF614-MPAR-102 Study with Full Enrollment of Part 2

Jun 11, 2025, 8:00 AM EDT - 3 months ago

Ensysce Biosciences Announces Speakers for Major Symposium at PAINWeek 2025

Jun 4, 2025, 8:00 AM EDT - 3 months ago

Ensysce Biosciences Awarded $5.3 Million in Continued NIDA Support to Advance Breakthrough Opioid Overdose Protection

May 13, 2025, 4:15 PM EDT - 4 months ago

Ensysce Biosciences Reports First Quarter 2025 Financial Results

May 12, 2025, 8:00 AM EDT - 4 months ago

Ensysce Biosciences Bolsters Management Team with Regulatory Expert

Apr 24, 2025, 4:15 PM EDT - 5 months ago

Ensysce Biosciences, Inc. Announces Closing of Exercise of Warrants for $2.2 Million Gross Proceeds

Apr 23, 2025, 5:11 PM EDT - 5 months ago

Ensysce Biosciences Stock Doubles In One Trading Session - Here's Why

Apr 23, 2025, 4:41 PM EDT - 5 months ago

Ensysce Biosciences, Inc. Announces Exercise of Warrants for $2.2 Million Gross Proceeds

Apr 23, 2025, 8:00 AM EDT - 5 months ago

Ensysce Biosciences Receives U.S. Patent for Groundbreaking Treatment of Opioid Use Disorder

Apr 15, 2025, 8:00 AM EDT - 5 months ago

Ensysce Biosciences Announces Positive Data from Opioid Overdose Protection Study

Mar 31, 2025, 8:00 AM EDT - 6 months ago

Ensysce Biosciences, Inc. Announces $1.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Mar 18, 2025, 8:00 AM EDT - 6 months ago

Ensysce Biosciences Announces PAINWeek 2025 Symposium and Recent Expert Panel Discussion on The State of the Nation in Pain

Mar 10, 2025, 4:15 PM EDT - 6 months ago

Ensysce Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results

Mar 5, 2025, 8:00 AM EST - 7 months ago

Ensysce Biosciences to Participate in the 37th Annual ROTH Conference

Mar 3, 2025, 9:43 AM EST - 7 months ago

Ensysce Biosciences CEO Dr. Lynn Kirkpatrick and Creighton University's Dr. Neel Pathak Discuss the Opioid Crisis and Next Generation Opioids

Feb 5, 2025, 8:00 AM EST - 8 months ago

Ensysce Biosciences Reports Continued Positive Progress in Groundbreaking Trial on PF614-MPAR, Comments on Current Landscape for Pain Treatment

Jan 22, 2025, 8:00 AM EST - 8 months ago

Ensysce Biosciences Announces Positive Interim Data for Breakthrough Therapy PF614-MPAR

Jan 8, 2025, 8:00 AM EST - 9 months ago

Ensysce Biosciences Issues Annual Shareholder Letter

Dec 23, 2024, 8:00 AM EST - 9 months ago

Ensysce Biosciences Regains Full Compliance with Nasdaq

Dec 10, 2024, 8:00 AM EST - 10 months ago

Ensysce Biosciences Announces Commercial Supplier for Breakthrough Overdose Protection Drug Product

Dec 4, 2024, 8:00 AM EST - 10 months ago

Ensysce Biosciences Announces Strategic Partnership for the Development and Commercial Launch of PF614 and PF614-MPAR

Dec 3, 2024, 4:15 PM EST - 10 months ago

Ensysce Biosciences Announces 1-for-15 Reverse Stock Split

Nov 26, 2024, 8:00 AM EST - 10 months ago

Ensysce Biosciences Completes Significant Milestone, Dosing First Subjects in Breakthrough Therapy PF614-MPAR Trial

Nov 12, 2024, 4:15 PM EST - 11 months ago

Ensysce Biosciences Reports Third Quarter 2024 Financial Results

Nov 7, 2024, 8:00 AM EST - 11 months ago

Ensysce Biosciences Receives Positive Nasdaq Listing Determination

Oct 8, 2024, 8:00 AM EDT - 1 year ago

Ensysce Biosciences Announces Leadership Team's Participation in the Annual Pain Therapeutics Summit

Oct 2, 2024, 8:00 AM EDT - 1 year ago

Ensysce Biosciences Provides Shareholder Update, Responds to Recent Shareholder Inquiries

Sep 27, 2024, 4:30 PM EDT - 1 year ago

Ensysce Biosciences Receives Notice from Nasdaq

Sep 24, 2024, 8:00 AM EDT - 1 year ago

Ensysce Biosciences Presenting at Upcoming Meetings

Sep 19, 2024, 7:00 AM EDT - 1 year ago

Ensysce Biosciences Submits Phase 3 Protocol to the FDA

Sep 13, 2024, 8:00 AM EDT - 1 year ago

Ensysce Biosciences Posts Video Updates from the IASP World Congress on Pain 2024

Aug 29, 2024, 8:00 AM EDT - 1 year ago

Ensysce Biosciences, Inc. Announces $5 Million Concurrent Registered Direct Offering and Exercise of Warrants

Aug 27, 2024, 2:30 PM EDT - 1 year ago

Ensysce Biosciences Announces IRB Approval for Key MPAR Study

Aug 27, 2024, 8:00 AM EDT - 1 year ago

Ensysce Biosciences Receives $14 Million NIH Grant for Clinical Development of Novel Opioid with Overdose Protection

Aug 14, 2024, 4:15 PM EDT - 1 year ago

Ensysce Biosciences Reports Second Quarter 2024 Financial Results

Aug 8, 2024, 8:25 AM EDT - 1 year ago

Ensysce Biosciences Provides Key Themes Following IASP 2024 Symposium

Jul 23, 2024, 8:00 AM EDT - 1 year ago

Ensysce Biosciences Provides Mid-Year 2024 Update

Jul 9, 2024, 8:00 AM EDT - 1 year ago

Ensysce Biosciences Hosts IASP 2024 Symposium and Presents Clinical Dataset

Jun 27, 2024, 8:00 AM EDT - 1 year ago

Ensysce Biosciences Discusses Key Themes from the EPHMRA 2024 Annual Meeting

Jun 25, 2024, 8:00 AM EDT - 1 year ago

Ensysce Biosciences Announces Partnership to Scale and Manufacture New Drug Candidate

Jun 6, 2024, 8:00 AM EDT - 1 year ago

Ensysce Biosciences Announces Major Milestone for Opioid Use Disorder Program

Jun 3, 2024, 8:00 AM EDT - 1 year ago

Ensysce Biosciences to Participate in the EPHMRA 2024 Annual Meeting

May 20, 2024, 8:00 AM EDT - 1 year ago

Ensysce Biosciences Continues Collaboration to Advance the Clinical Development of Innovative Overdose Protection Platform

May 13, 2024, 8:00 AM EDT - 1 year ago

Ensysce Biosciences Reports First Quarter 2024 Financial Results

KelsoWins Sep. 21 at 5:07 AM

0 · Reply

ThereAre4Lights Sep. 17 at 2:12 PM

$ENSC some short has been slowly unloading the past few days, check the fidelity shortable shares available and borrow rate

0 · Reply

Fowlee06 Sep. 16 at 11:55 AM

$ENSC

0 · Reply

EnsysceBiosciences Sep. 15 at 12:40 PM

0 · Reply

EnsysceBiosciences Sep. 10 at 12:59 PM

3 · Reply

danstra1 Sep. 10 at 10:04 AM

0 · Reply

HeisenbergCT Sep. 9 at 1:41 PM

1 · Reply

EnsysceBiosciences Sep. 8 at 1:32 PM

1 · Reply

HeisenbergCT Sep. 8 at 12:51 PM

$ENSC there's a direct correlation between the size of my holding and the frequency and number of my posts to this board.

1 · Reply

HeisenbergCT Sep. 8 at 12:11 PM

0 · Reply

HeisenbergCT Sep. 5 at 12:44 PM

$ENSC by the way, a lower rate environment is a major positive for struggling biotech companies with a high cash burn rate. .. If we get rate cutes (long overdue imo), Ensysce will benefit.

1 · Reply

EnsysceBiosciences Sep. 4 at 2:48 PM

$ENSC Ensysce Biosciences Showcases Urgent Need for Safer Opioids at PAINWeek 2025 Symposium View key takeaways from its standing-room-only symposium, “Pain Management, RE-Invented: A New Era for Analgesia”, held September 3, 2025, at PAINWeek in Las Vegas—the world’s largest pain management conference. https://finance.yahoo.com/news/ensysce-biosciences-showcases-urgent-safer-120000471.html

3 · Reply

Mateine Sep. 4 at 12:04 PM

$ENSC https://ir.ensysce.com/news/press-releases/detail/199/ensysce-biosciences-showcases-urgent-need-for-safer-opioids

1 · Reply

Abdujabbar90 Sep. 3 at 7:48 PM

$ENSC after 2.4 going to 10 dollars when FDA APPROVED COME

3 · Reply

Wallstreetiscriminal Sep. 3 at 7:09 PM

$ENSC I thought you were referring to the stock when you said PAIN week. I immediately thought, that’s not right. It’s been PAINFUL holding this for many months, not just a week!

1 · Reply

EnsysceBiosciences Sep. 2 at 2:27 PM

$ENSC 📢 Tomorrow at PAINWeek 2025 Dr. William Schmidt, Chief Medical Officer of Ensysce Biosciences, will speak at PAINWeek — the largest pain conference in the world. 🔹 Symposium: “Pain Management, RE-Invented: A New Era for Analgesia” 🔹 Date: September 3, 2025, At 12 noon PT. 🔹 Time: 12:00 PM Pacific Time Join us live to hear how Ensysce is pioneering the future of safer, more effective pain treatments. #ENSC #PAINWeek #PainManagement #DrugSafety #Innovation

2 · Reply

turbjade Sep. 2 at 12:32 PM

$ENSC FDA sold out patients for years, no approval for MPAR after rubber stamping death for hundreds of thousands, maybe millions. Now kratom is killing too, but people don't have access to safe pain relief. At a minumum, the FDA officials that approved OxyContin should have been tried for treason for betraying the American people. Probably the entire FDA should be dismantled.

0 · Reply

HeisenbergCT Sep. 2 at 12:14 PM

$ENSC this might start getting interesting... Fall 2025 - June 2026 was the timeframe I've been looking at for possible game-changing news for ENSC. Post Labor day kicks it off.. so yes, I've bought shares.... round 3 for me. Wiped out the first time, hammered the second time, and now the third....?? we'll see.. three strikes or 3's a charm??

0 · Reply

ttesty Aug. 31 at 11:16 AM

$ENSC... how about pain relief for investors? Like when Pfizer buys you for $1/share. $CTOR.

0 · Reply

astonm Aug. 28 at 2:26 PM

$ENSC

0 · Reply

teachutrades Aug. 28 at 1:43 AM

$ENSC they will be attending a major conference during pain week, Sept. 3rd. I expect some major updates!

3 · Reply

Nhred1999 Aug. 27 at 4:27 PM

$ENSC So this is getting absurd with this stock. According to the Feds clinical trials.gov ENSC hasn’t updated the phase 3 trial since 10/2024(not started)The phase 1 trial is still recruiting and hasn’t been updated since 5/2025. Yet their latest PR is that some exec volunteered to be on the planning committee for fierce pharma…

2 · Reply

Market Cap	6.32M
Revenue (ttm)	5.21M
Net Income (ttm)	-7.99M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-153.36%
Debt to Equity Ratio	0.00

Volume	74,400
Avg Vol	399,374
Day's Range	N/A - N/A
Shares Out	2.97M
Stochastic %K	65%
Beta	1.00
Analysts	Strong Buy
Price Target	$18.45